SRTD biotech, a Jülich, Germany-based company providing RNA-based therapeutics, raised an undisclosed amount in Seed funding.
The round was led by High-Tech Gründerfonds (HTGF), alongside business angels.
The company intends to use the funds to expand operations and its R&D efforts.
Founded by Dr Bernd Hoffmann and Dr Heribert Bohlen, SRTD biotech is developing RNA-based therapeutics that are active only in diseased cells. It is using the novel approach of “selectively expressed RNAs”, or seRNAs, as a first step in the development of a therapy for liver cancer and is exploiting the possibilities of its modular platform technology for further development in the field of cancer therapeutics and beyond.
FinSMEs
02/12/2024